Trial Profile
A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Oxaliplatin (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 23 Oct 2009 New trial record